Preclinical investigations into the role of complement in closed-head TBI are somewhat limited. To our knowledge, no studies have examined the role of complement in repetitive mild closed head injury ...
Neuromyelitis optica spectrum disorder (NMOSD) is a rare neurological autoimmune disease caused by autoantibodies targeting the astrocytic water channel aquaporin-4 (AQP4). Binding to AQP4 initiates ...
Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
The figure focuses on complement activation by means of the alternative pathway because it is the one responsible for hemolysis in PNH. The lightning bolt symbolizes the spontaneous hydrolytic ...
Repurposing complement inhibitors to see whether they are effective against neurodegenerative diseases is already in development. (Artur Plawgo/iStock/Getty Images Plus) With Alzheimer’s disease ...
The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3, double-blind ...
These findings suggest complement protein levels may be an important biomarker for type 1 diabetes. Disruption of the complement system appears to precede the onset of islet autoimmunity (IA), making ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
PASC, which is otherwise known as long COVID, arises following the recovery from acute infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for ...
Priority review for ravulizumab in IgA nephropathy could establish the first C5 complement inhibitor label in this indication, addressing substantial residual progression risk despite current standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results